Literature DB >> 9409257

Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.

J R Horowitz1, A Rivard, R van der Zee, M Hariawala, D D Sheriff, D D Esakof, G M Chaudhry, J F Symes, J M Isner.   

Abstract

In vitro studies suggest that vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) may stimulate release of nitric oxide (NO) from endothelial cells. To investigate the hemodynamic consequences of recombinant VEGF/VPF administered in vivo, recombinant human VEGF/VPF was administered as a bolus dose of 500 micrograms to anesthetized (n = 6) or conscious (n = 5) New Zealand White rabbits, as well as anesthetized rabbits with diet-induced hypercholesterolemia (HC; n = 7). Anesthetized Yorkshire farm pigs (no specific dietary pretreatment) were studied before and after receiving 500 micrograms intravenous (IV; n = 5) or intracoronary (IC; n = 5) VEGF/VPF. In anesthetized, normal rabbits, mean arterial pressure (MAP) fell by 20.5 +/- 1.4% (P < .05 versus baseline) within 3 minutes after IV VEGF/VPF. Pretreatment with N omega-nitro-L-arginine caused a significant inhibition of VEGF/VPF-induced hypotension. In conscious, normal rabbits, VEGF/VPF produced a consistent though lesser reduction in MAP. The fall in MAP induced by VEGF/VPF in anesthetized, HC rabbits (21.5 +/- 2.5% from baseline) was no different from that observed in normal anesthetized rabbits. In pigs, both IV and IC administration of VEGF/VPF produced a prompt reduction in MAP. Heart rate increased, while cardiac output, stroke volume, left atrial pressure, and total peripheral resistance all declined to a similar, statistically significant degree in both IV and IC groups. Epicardial echocardiography disclosed neither global nor segmental wall motion abnormalities in response to VEGF/VPF. We conclude that (1) VEGF/VPF-stimulated release of NO, previously suggested in vitro, occurs in vivo; (2) this finding suggests that functional VEGF/VPF receptors are present on quiescent adult endothelium, consistent with a maintenance function for VEGF/VPF, which may include regulation of NO; and (3) the preserved response of HC rabbits suggests that endothelial cell receptors for VEGF/VPF are spared in the setting of hypercholesterolemia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9409257     DOI: 10.1161/01.atv.17.11.2793

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  64 in total

Review 1.  Clinical applications of vascular gene therapy.

Authors:  J Rutanen; T T Rissanen; A Kivelä; I Vajanto; S Ylä-Herttuala
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

Review 2.  Roles for VEGF in the adult.

Authors:  Arindel S R Maharaj; Patricia A D'Amore
Journal:  Microvasc Res       Date:  2007-04-06       Impact factor: 3.514

Review 3.  Adverse effects of anticancer agents that target the VEGF pathway.

Authors:  Helen X Chen; Jessica N Cleck
Journal:  Nat Rev Clin Oncol       Date:  2009-07-07       Impact factor: 66.675

4.  The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.

Authors:  M Skinner; K Philp; D Lengel; L Coverley; E Lamm Bergström; P Glaves; H Musgrove; H Prior; M Braddock; R Huby; J O Curwen; P Duffy; A R Harmer
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

5.  Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

Authors:  Suzanne E Dahlberg; Alan B Sandler; Julie R Brahmer; Joan H Schiller; David H Johnson
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

Review 6.  Molecular mechanisms underlying cardiotoxicity of novel cancer therapeutics.

Authors:  Simon Braumann; Stephan Baldus; Roman Pfister
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

7.  VEGF Receptor-2-Linked PI3K/Calpain/SIRT1 Activation Mediates Retinal Arteriolar Dilations to VEGF and Shear Stress.

Authors:  Travis W Hein; Robert H Rosa; Yi Ren; Wenjuan Xu; Lih Kuo
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-08       Impact factor: 4.799

8.  Rapid development of hypertension by sorafenib: toxicity or target?

Authors:  Benjamin D Humphreys; Michael B Atkins
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

Review 9.  Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.

Authors:  Wei-Xiang Qi; Ai-Na He; Zan Shen; Yang Yao
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

Review 10.  Therapeutic myocardial angiogenesis.

Authors:  Marie-Ange Renault; Douglas W Losordo
Journal:  Microvasc Res       Date:  2007-09-07       Impact factor: 3.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.